Bruton tyrosine kinase inhibitors (BTKi) have transformed the treatment of B-cell malignancies. but intolerance has often led to their discontinuation. The phase 1/2 BRUIN study evaluated pirtobrutinib. a highly selective non-covalent (reversible) BTKi. https://canadabrass.shop/product-category/new-stocks-and-fore-ends/